Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 45

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 45
---
 including our competitors, and our competitors could market competing products and technology. In
addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties, and such cooperation
may not be provided to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations
and prospects.

Further, we rely on a combination of trade secrets,
know-how, technology and nondisclosure, and other contractual agreements and technical measures to protect our rights in the technology.
If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor,
our business and financial condition could be materially and adversely affected. The laws of some foreign countries do not protect our
proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary
rights in these countries.

Our success depends in significant part on our
ability to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to our drug candidates and
technology and to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights of
others. If we are unable to obtain and maintain sufficient intellectual property protection for our drug candidates or other drug candidates
that we may identify, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors and
other third parties could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize
our drug candidates and other drug candidates that we may pursue may be impaired.

<div align='center'>20</div>

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on our business.

Our success depends, in part, on our ability to
protect our proprietary rights to the technologies used in our product candidates. We depend heavily upon confidentiality agreements with
our officers, employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures may not afford
us complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure of confidential
information. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively against
us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation